Supernus Pharmaceuticals Stock Today
| SUPN Stock | USD 32.15 0.17 0.53% |
PerformanceVery Weak
| Odds Of DistressLow
|
Supernus Pharmaceuticals is selling at 32.15 as of the 23rd of March 2025; that is 0.53 percent decrease since the beginning of the trading day. The stock's open price was 32.32. Supernus Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of May 2012 | Category Healthcare | Classification Health Care |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. The company has 55.81 M outstanding shares of which 5.72 M shares are at this time shorted by private and institutional investors with about 10.08 trading days to cover. More on Supernus Pharmaceuticals
Moving together with Supernus Stock
Moving against Supernus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Supernus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Jack Khattar | ||||
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Trump Equities, Obamacare Repeal, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsSupernus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Supernus Pharmaceuticals' financial leverage. It provides some insight into what part of Supernus Pharmaceuticals' total assets is financed by creditors.
| |||||
Supernus Pharmaceuticals (SUPN) is traded on NASDAQ Exchange in USA. It is located in 9715 Key West Avenue, Rockville, MD, United States, 20850 and employs 674 people. Supernus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.79 B. Supernus Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 55.81 M outstanding shares of which 5.72 M shares are at this time shorted by private and institutional investors with about 10.08 trading days to cover.
Supernus Pharmaceuticals currently holds about 360.79 M in cash with 171.95 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.74.
Check Supernus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Supernus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Supernus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Supernus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Supernus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Supernus Ownership Details
Supernus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Loomis, Sayles & Company Lp | 2024-12-31 | 1.5 M | |
| Gw&k Investment Management, Llc | 2024-12-31 | 1.2 M | |
| American Century Companies Inc | 2024-12-31 | 1.1 M | |
| Aristotle Capital Boston, Llc | 2024-12-31 | 1.1 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 934 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 753.4 K | |
| Northern Trust Corp | 2024-12-31 | 717.2 K | |
| Victory Capital Management Inc. | 2024-12-31 | 714.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 677.7 K | |
| Blackrock Inc | 2024-12-31 | 10 M | |
| Vanguard Group Inc | 2024-12-31 | 6.2 M |
Supernus Pharmaceuticals Historical Income Statement
Supernus Stock Against Markets
Supernus Pharmaceuticals Corporate Management
| Padmanabh Bhatt | Chief Scientific Officer and Sr. VP of Intellectual Property | Profile | |
| Tami Martin | VP Affairs | Profile | |
| Jeff Bozick | Senior Chain | Profile | |
| Kevin Esq | Compliance Officer | Profile | |
| Taylor Raiford | Senior Sales | Profile | |
| Bryan Roecklein | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14.447 | Earnings Share 1.32 | Revenue Per Share | Quarterly Revenue Growth 0.06 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.